Stifel Reiterates Nektar Therapeutics (NKTR) at Buy, But Expects Deflation in Stock, Sees NKTR-358 as Lead Asset Going Forward
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR), following the company's PIVOT-IO Phase 3 data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
